The Netherlands is home to an advanced medical biotechnology sector, supported by a strong scientific foundation and the rise of innovative companies specializing in new testing techniques. The sector's growth is further propelled by the European Medicines Agency (EMA). With its leading advancements in nanotechnology, microfluidics, and optics, the Netherlands provides a robust platform for innovation. Besides the intended use of test innovation in combating future pandemics, faster and better testing capabilities offer a multitude of opportunities both in the biomedical field and beyond. P3Dx creates economic opportunities for companies developing test innovations, including in fields outside the medical domain such as environmental or agriculture applications.
Opportunities
P3Dx acts as a driver for the development of innovative testing methods, during a pandemic and beyond. In doing so, it creates economic opportunities and contributes to the positioning of the Netherlands in the international arena.
P3Dx:
Establishes a shared vision and innovation roadmap for pandemic pathogen detection, aligned with national preparedness programmes and structures.
Works with partners on test innovations for various applications (use cases).
Translates innovations in pandemic testing methods to applications outside pandemic contexts, e.g. in agriculture, horticulture and environment.
Generates proof of concept sample studies of innovative tests.
Contact
Want to know more about the programme or join the ecosystem? Get in touch with Scientific lead Bart Keijser at bart.keijser@tno.nl.
E-mail Bart Keijser
P3Dx on LinkedIn